Trial reportNature metabolism2024
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.
Trial report in Nature metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.JAMA ophthalmology · 2025Pooled it
- Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.International journal of obesity (2005) · 2025Pooled it
- Type 2 diabetes subtypes for precision medicine: methodological challenges and alternative prediction-based approaches.Diabetologia · 2026Review
- Article
- Subtypes of newly diagnosed type 2 diabetes and risk of complications: analysis of electronic health records in the USA.Diabetologia · 2026Article
- Type 2 diabetes subphenotypes are associated with differential outcomes after metabolic and bariatric surgery: An international multicentre retrospective cohort study.Diabetes, obesity & metabolism · 2026Article
- Five tenets for advancing evidence-based precision medicine.Nature medicine · 2026Review
- Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humans.Hormones (Athens, Greece) · 2026Review
- A machine learning model for optimizing treatment of patients with poorly controlled type 2 diabetes.Communications medicine · 2026Article
- Beyond Glucose-Rethinking Prediabetes for Precision Prevention.Diabetes care · 2026Review
- The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Nutrigenomics meets multi-omics: integrating genetic, metabolic, and microbiome data for personalized nutrition strategies.Genes & nutrition · 2025Review
- Type 2 diabetes subtypes classification: a global reckoning with heterogeneity.The lancet. Diabetes & endocrinology · 2025Article
- Effectiveness of GLP-1RA according to different type 2 diabetes phenotypes: A retrospective study.Diabetes, obesity & metabolism · 2025Article
- Examining the Omission of Dietary Quality Data in Glucagon-Like Peptide 1 Clinical Trials: A Scoping Review.Advances in nutrition (Bethesda, Md.) · 2025Article
- Recognising, quantifying and accounting for classification uncertainty in type 2 diabetes subtypes.Diabetologia · 2025Observational
- Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes.Nature medicine · 2025Article
- Review
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024 · on this mapReview
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The limited understanding of the heterogeneity in the treatment response to antidiabetic drugs contributes to metabolic deterioration and cardiovascular complications
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.